Filgotinib

Pipeline in a product opportunity



Galápagos

Filgotinib

potential for 5 launches in next 4 years



RA: rheumatoid arthritis; CD: Crohn's disease; UC: ulcerative colitis; AS: ankylosing spondylitis; PsA: psoriatic arthritis

Galápagos

Global inflammation market $65B by 2027

Estimated market size, $B



RA: rheumatoid arthritis; CD: Crohn's disease; UC: ulcerative colitis; AS: ankylosing spondylitis; PsA: psoriatic arthritis
Source: Galapagos estimates, Decision Resources Group

Galápagos

Phase 3 FINCH program in RA

100 and 200 mg

FINCH 1: MTX-IR	1,759	52 weeks	ACR20 at W12 MTX add-on adalimumab control radiographic assessment
FINCH 2: biologic-IR	449	24 weeks	ACR20 at W12 cDMARD add-on
FINCH 3: MTX-naïve	1,252	52 weeks	ACR20 at W24 monotherapy, + MTX arms radiographic assessment

ACR20: primary endpoint

FINCH1

W12



FIL: filgotinib; ADA: adalimumab; MTX: methotrexate; PBO: placebo
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX

Galápagos

ACR20/50/70

FINCH1

W12



FIL: filgotinib; ADA: adalimumab; MTX: methotrexate; PBO: placebo
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX
Press release. Gilead Sciences, Inc. and Galapagos NV. March 28, 2019

Galápagos

LDA & clinical remission

FINCH1

W12



**p<0.001, **p<0.01, non-inferiority to ADA; # p<0.01, superiority to ADA; † Comparison not adjusted for multiplicity*
FIL: filgotinib; ADA: adalimumab; MTX: methotrexate; PBO: placebo; CRP: C-reactive protein; DAS: disease activity score; LDA: low disease activity
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX
Press release. Gilead Sciences, Inc. and Galapagos NV. March 28, 2019

Galápagos

Radiographic progression

FINCH1

W24



FIL: filgotinib; ADA: adalimumab; MTX: methotrexate; PBO: placebo; mTSS: modified total Sharp scores
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX

Galápagos

ACR20: primary endpoint

FINCH 2

W12



FIL: filgotinib; MTX: methotrexate; PBO: placebo; csDMARD: conventional synthetic disease-modifying antirheumatic drug
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX
Data derived from Genovese MC, et al. ACR Annual Meeting 2018; abstract L06; poster presentation

Galápagos

ACR20/50/70

FINCH 2

W12



FIL: filgotinib; MTX: methotrexate; PBO: placebo; csDMARD: conventional synthetic disease-modifying antirheumatic drug
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX
Data derived from Genovese MC, et al. ACR Annual Meeting 2018; abstract L06; poster presentation

Galápagos

LDA & clinical remission

FINCH 2

W12



FIL: filgotinib; MTX: methotrexate; PBO: placebo; csDMARD: conventional synthetic disease-modifying antirheumatic drug;
CRP: C-reactive protein; DAS: disease activity score; LDA: low disease activity
Note: MTX-IR population (inadequate response to MTX); all arms were on a stable dose of MTX
Data derived from Genovese MC, et al. ACR Annual Meeting 2018; abstract L06; poster presentation

Galápagos

ACR20: primary endpoint

FINCH3

W24



FIL: filgotinib; MTX: methotrexate; PBO: placebo
Note: MTX-naïve population

Galápagos

ACR20/50/70

FINCH3

W24



**Comparison not adjusted for multiplicity*
FIL: filgotinib; MTX: methotrexate; PBO: placebo
Note: MTX-naïve population
Press release. Gilead Sciences, Inc. and Galapagos NV. March 28, 2019

Galápagos

Clinical remission

FINCH3

W24



**Comparison not adjusted for multiplicity*
FIL: filgotinib; MTX: methotrexate; PBO: placebo
Note: MTX-naïve population
Press release. Gilead Sciences, Inc. and Galapagos NV. March 28, 2019

Galápagos

Filgotinib's JAK1 inhibition addresses inflammation…

Active in MTX-naïve to bDMARD-IR patients

Treatment effect maintained (156 weeks)

Clinical benefits seen early

Galápagos

…without liabilities of off-target effects

FINCH program up to week 24

n (%)	PBO/MTX	adalimumab 40 mg EOW	filgotinib total
	N=1039	N=325	N=2088
serious infection	10 (1.0)	8 (2.5)	**29 (1.4)**
herpes zoster	4 (0.4)	2 (0.6)	**12 (0.6)**
DVT/PE	3 (0.3)	0 (0)	**1 (<0.1)^**
deaths	2 (0.2)	0 (0)	**4 (0.2)**

^ = excludes 1 case of retinal vein occlusion
Source: Winthrop et al., ACR 2019; Kavanaugh et al., ACR 2019

Filgotinib selectivity



From: "Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations," McInnes et al, ACR 2017

Galápagos

Normalizing RA laboratory abnormalities



Note: Data above derived from Westhovens et al, and Kavanaugh et al

Galápagos

Ulcerative colitis (UC)

Chronic inflammation of the large intestine

Common symptoms:

- loose and urgent bowel movements
- bloody stool
- persistent diarrhea and abdominal pain



Galápagos

Phase 3 SELECTION program in UC



Galápagos

SELECTION population

selected baseline characteristics	biologic-naïve cohort n=659	biologic-experienced cohort n=689
Mayo Clinic Score ≥9	52%	74%
previous exposure to TNFα & integrin receptor antagonist	N/A	51%

Data on File. Gilead Sciences, Inc. and Galapagos NV. May 2020.

Galápagos

SELECTION: primary endpoint

assessed at week 10 (induction) and week 58 (maintenance)



Galápagos

Induction primary endpoint achieved



filgotinib 100 mg did not meet primary endpoint at week 10

Data on File. Gilead Sciences, Inc. and Galapagos NV. May 2020.

Galápagos

Maintenance primary endpoint achieved



Data on File. Gilead Sciences, Inc. and Galapagos NV. May 2020.

Galápagos

SELECTION safety data

INDUCTION TRIAL SAFETY RESULTS

events	filgotinib 200 mg	filgotinib 100 mg	placebo
SAE in biologic-naïve patients	1.2%	4.7%	2.9%
SAE in biologic-experienced patients	7.3%	5.3%	6.3%

MAINTENANCE TRIAL SAFETY RESULTS

events	filgotinib 200 mg	placebo[1]	filgotinib 100 mg	placebo[2]
SAE	4.5%	-	4.5%	7.7%
deaths*	2	-	-	-

*Two deaths were observed in the filgotinib 200 mg treatment group in the maintenance trial; one patient with pre-existing asthma died due to asthma exacerbation, and the second patient with pre-existing atherosclerosis died due to left ventricular heart failure per autopsy report. Neither death was assessed as related to study drug by the investigator.

"Rates of serious infections, herpes zoster, venous thrombosis, pulmonary embolism and gastrointestinal perforation were low and comparable across treatment groups in both the induction and maintenance phases of the trial"

FILGO: filgotinib; PBO: placebo; SAE: serious adverse event
[1]Placebo for filgotinib 200 mg group; [2]Placebo for filgotinib 100 mg group
Data on file. Gilead Sciences, Inc. and Galapagos NV. May 2020.

Galápagos

Filgotinib: GLPG's commercial footprint

Rheuma & IBD – Benelux

Rheuma – France/Italy/Spain

IBD – UK/Germany



Ramping up for competitive launch of filgotinib in RA in H2 2020

Galápagos